Immune Pharmaceuticals Holds First R&D Day On September 8, 2015

Sep 3, 2015

NEW YORK, Sept. 3, 2015 /PRNewswire/ -- Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) ("Immune" or the "Company") announced today that its first R&D day will take place on September 8, 2015 at 2pm at the Alexandria Center for Life Science in New York City.

The Immune R&D day will focus on the company pipeline in Precision Immuno-Therapy for Inflammatory Diseases and Cancer and will feature several keynote speakers:

  • Robert Goldberg, PhD will present on the importance of Precision Medicine to create value for patients and for the healthcare system.
  • Yaron Ilan, MD – Chairman of Medicine, Professor of Gastro-Enterology and Liver Diseases at Hadassah Hospital, Jerusalem, IL, will present the role of eotaxin-1 as a key regulator of Immuno-Inflammation and the clinical potential of bertilimumab
  • Neil Korman, MD- Chairman of Dermatology, Case Western School     of Medicine, Cleveland, OH will present the role of eotaxin-1 in Dermatology and the clinical potential of bertilimumab.
  • Dr. Boris Shor, Immune's Executive Director, R&D and Dr. Zahra Shahrockh, Chief Development Officer, STC biologics will present the company development plans for NanomAbs, for the targeted delivery of cancer drugs.

Dr. Daniel Teper, Immune's CEO will also present at the Rodman and Renshaw's 17th Annual Global Investment Conference on Thursday, September 10th, 2015 at 3 pm the St Regis Hotel, Astor Suite A- 2nd Floor, in New York City.

Webcast will be accessible within a few days and for the next 90 days at

If you are interested in attending the Immune R&D Day or meet Immune management at or around the Rodman conference please contact Anna Baran at

About Immune Pharmaceuticals  

Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. The Company recently expanded its portfolio in immuno-dermatology, topical nano-formulated Cyclosporine A (CsA) for the treatment of psoriasis and atopic dermatitis. Immune's pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics. Other indications planned for development include Crohn's disease, severe asthma and NASH (liver disease).

For more information, visit Immune's website at 

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for Bertilimumab or AmiKet will not be successful; the risk that Bertilimumab, AmiKet or compounds arising from our NanomAbs program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger- scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings, which are available at or at You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE Immune Pharmaceuticals, Inc.

For further information: Immune Pharmaceuticals, Inc., Christine J. Petraglia, Director, Corporate Communications, 646.440.9310,

print email rss